RE: meanwhile19 Mar 2023 15:31
RNS dated 18 January 2023,'Whilst the current order book is £2.5m and further orders are expected, a number of orders will move into FY24.
So off to a good start in new financial year, world leading company with cash in bank with strategy to increase growth within the biggest market, and other orders just renewing in China, and partner in United Arab Emirates jyst signing a 3 year contract with Dubai Health Authority. Looks like will be very busy this year and return to growth can be expected. Target price of 12p or above for 90 days. Directors saying company undervalued, 2 directors buying a further million shares each. The CEO a the finance director. So should know what's happening. Take notice of company in RNSs or bitter ex employee/director/shareholder or just a bitter poster.